

Date: 2009-Jun-12

To: Centre Representatives
Ethics Representatives
Contact Clinical Research Associates

From: Ralph Meyer, Director, NCIC Clinical Trials Group

RE: PERMANENT CLOSURE NOTICE FOR 3 ADDITIONAL TRIALS

Dear Participants,

We are writing today as a follow-up to our last notification to inform centres of 3 additional trials that have now been deemed permanently closed. Therefore, no further follow-up data nor REB approval of these trials is required.

Health Canada and industry partners that were associated with Canadian drug supply and distribution have been notified of these final trial closures where applicable. Please notify your REB of any outstanding ethics documents for the applicable trials below and of the final completion of these trials. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.


Please remember that notification of permanent study closure (and not notification of final analysis or publication) must be received from NCIC CTG in order for data collection, as stipulated in the protocol, and REB approval to cease. NCIC CTG will also continue to notify participating centres when trial related records no longer need to be retained in accordance with all applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

*Effective immediately, data submission and REB approval for the following **Intergroup- led** trial is no longer required:*

<i>Disease Site</i>	<i>Trial Code</i>	<i>Study Coordinator Contact</i>
Breast:	MA.10 (10921)	Christine Bertrim cbertrim@ctg.queensu.ca

<i>Effective immediately, data submission and REB approval for the following <u>NCIC CTG-led</u> trials are no longer required:</i>		
<i>Disease Site</i>	<i>Trial Code</i>	<i>Study Coordinator Contact</i>
Breast:	MA.5	Christine Bertrim cbertrim@ctg.queensu.ca
Gastrointestinal:	CO.3	Christine Bertrim cbertrim@ctg.queensu.ca

Yours sincerely,



Ralph Meyer, MD, FRCP(C)
Director, NCIC Clinical Trials Group
Professor, Department of Oncology, Medicine and
Community Health & Epidemiology
Queen's University